Currently Viewing:
American Society of Hematology
Currently Reading
Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
December 07, 2017
Significant Economic Burden Associated With Various AML Treatment Episodes
December 08, 2017
The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life
December 08, 2017
Using Time Spent at Home to Measure End-of-Life Care Quality
December 09, 2017
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
December 10, 2017
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being
December 10, 2017
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10, 2017
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017

Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care

Thomas LeBlanc, MD, of the Duke Cancer Institute, addresses the importance of adding a palliative care specialist to the cancer care team.
 


Thomas LeBlanc, MD, of the Duke Cancer Institute, addresses the importance of adding a palliative care specialist to the cancer care team.

Transcript

What is the importance of involving carious team members in care for patients with blood cancers to help improve their patient experience?

Shared decision making is one of the biggest challenges we face in modern cancer care today. Although the Institute of Medicine, now known as the National Academy of Medicine, has been saying we should be doing shared decision making for about a decade or more now, it’s something that most of us struggle with in practice and most of us have never formally been trained in how to do it. It’s like the old medical model of see one, do one, teach one, and a lot of us really fumble through this doing it in a way that ends up being more of a superficial discussion about risks and benefits of treatment rather than a more substantive discussion about what’s important to that person.

So, the palliative care team, which includes folks who have specialized training in difficult communication and listening to people’s goals, values, and preferences really can be helpful in facilitating shared decision making in cancer care, especially in those situations where we’re quite uncertain about what the outcome is going to be, maybe the prognosis looks statistically poor but we’re still hoping there could be a good outcome or maybe a risky treatment like stem cell transplantation. This is when we really need to elicit people’s goals, values, and preferences and then tell them more about the risks and benefits of treatment but to map those up to what is important to them and help figure out together what the right treatment may be.

We’ve been finding in research presented here at ASH by my colleague Dr. El-Jawahri at Mass General and some other recent studies over recent years that many patients with cancer actually don’t want to be the primary decision maker about their treatment and yet most physicians don’t feel comfortable about making treatment recommendations and we want to just tell people here are the risks and benefits, here are the options, what do you want to do? Make a choice. That’s actually not how many people want to make decisions. We really have to flip this paradigm on it’s head and get more comfortable with diagnosing people’s preferences, which is really a foreign concept for many of us.

How do we actually ask questions that elicit patient’s preferences, goals, and values and then plug those in with what we know about the disease that we’re experts on, what we know about the treatment and the likely outcomes that we can really attest to with our medical expertise and help them figure out how that maps up with what’s actually important to them as people. It’s incredibly challenging and certainly easier to talk about than to actually do well, but it’s an area that we need to focus on over in the next several years to improve patient centered care and truly personalize care where the treatment that’s recommended and prescribed really matches up with the goals, values, and preferences of that person.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up